Research into cannabigerol is in its infancy but has shown promise for addressing a diverse array of therapeutic needs. Based on its pharmacodynamics, here we highlight potential indications for CBG and its derivatives to improve available drug treatment regimens for selected diseases and medical conditions.
First, there is potential for CBG as a major player in the treatment of metabolic disease as described by its action on the PPAR family of receptors to improve insulin sensitivity and adipogenesis.
Second, several studies have described the neuroprotective effects of CBG through action on the PPAR family of receptors. CBG may play a role for improving quality of life in these vulnerable populations, as the few drugs currently available for neurodegenerative diseases also carry uncomfortable and disabling side effects.
Third, similar to other phytocannabinoid derivatives, CBG may play an important role for improving the drug cocktails of patients who struggle with disorders of executive function, such as schizophrenia and ADHD. Researchers have studied the effects of CBG as a safe appetite stimulant in chemotherapy-related appetite suppression in vivo and as an agent that reduces in vitro signs of pathology in colitis and colorectal cancer.
In closing, although there is much to suggest that CBG may provide alternative therapeutics for a number of disorders, much is left to learn.